期刊文献+

阿托伐他汀对冠状动脉介入治疗术后血清单核细胞趋化蛋白-1、白细胞介素-10和高敏C反应蛋白的影响 被引量:35

Atorvastatin impacts the serum MCP-1,IL-10 and hs-CRP levels in patients with ACS after PCI
原文传递
导出
摘要 目的:探讨阿托伐他汀对经皮冠状动脉介入治疗术(PCI)后血清单核细胞趋化蛋白-1(MCP-1)、白细胞介素-10(IL-10)和高敏C反应蛋白(hs-CRP)的影响。方法:62例接受PCI的急性冠状动脉综合征(ACS)患者随机分为治疗组和对照组,分别给予阿托伐他汀钙片40mg(31例)和10mg(31例)每日1次口服。于术前及术后24h、1周测定血清hs-CRP、MCP-1和IL-10水平。MCP-1、IL-10检测采用酶联免疫吸附法,hs-CRP采用免疫比浊法。结果:①2组hs-CRP、MCP-1水平术后24h升高(均P<0.01),术后1周低于术后24h(均P<0.01),治疗组下降更显著,恢复到术前水平。②2组IL-10水平术后24h升高(均P<0.01),术后1周进一步升高(均P<0.01),治疗组明显高于对照组(P<0.01)。③2组MCP-1/IL-10比值术后24h增高(P<0.05),术后1周下降(P<0.01),治疗组较对照组下降更显著(P<0.01)。结论:ACS患者PCI后使用大剂量阿托伐他汀能促进hsCRP、MCP-1和MCP-1/IL-10下降和IL-10水平升高。 Objective: To investigate the effects of atorvastatin on serum monncyte chemoattractant protein-1 (MCP-1), interleukin-10(IL-10) and high sensitive C-reactive protein(hsCRP) in patients with acute coronary syndrome (ACS) after percutaneous transluminal coronary intervention (PCI). Method: Sixty-two patients with ACS after PCI were divided into the treatment group (n= 31) and control group (n= 31), separately intaking atorvastatin calcium tablet 40 mg or 10 mg qd. The serum MCP-1, IL-10 were determined by enzyme linked immunosorbent assay and the serum hs-CRP by immunoturbidimetry before and after PCI 24 h and 1 week. Result: (1) The serum hsCRP, MCP-1 levels in two groups were increased at 24 h and decreased significantly at 1 week post- PCI, especially in treatment group. (2)In two groups, the level of IL-10 increased at 24 h and continued rise to 1 week post-PCI,especially in treatment group. (3)MCP-1/IL-10 ratio was higher at 24 h post-PCI and lower at 1 week post-PCI in treatment group than control group. (P〈0. 01). Conclusion: Intaking large dose atorvastatin in patient with ACS after PCI contributes to decrease hsCRP, MCP-1 and MCP-1/IL -10 ratio while increase IL-10.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2009年第7期491-493,共3页 Journal of Clinical Cardiology
基金 包头市医药卫生科技项目(No:2007-38)
关键词 急性冠状动脉综合征 阿托伐他汀 单核细胞趋化蛋白-1 白细胞介素-10 高敏C反应蛋白 acute coronary syndrome atorvastatin chemoattractant protein-1, interteukin-lO high sensitive C-reactive protein
  • 引文网络
  • 相关文献

参考文献1

二级参考文献5

  • 1Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial.JAMA,2001,285:1711-1718.
  • 2Tyagi SC,Meyer L,Schmaltz RA,et al.Proteinases and restenosis in the human coronary artery:extracellular matrix production exceeds the expression of proteolytic activity.Atherosclerosis,1995,116:43-57.
  • 3Rosenson RS,Tangney CC.Antiatherothrombotic properties of statin:implications for cardiovascular event reduction.JAMA,1998,279:1643-1650.
  • 4Cleeman JI.Executive summary of the third report of the national cholesterol education program(NCEP) expert panel on detection,and treatment of high blood cholesterol in adults (adult treatment panel).JAMA,2001,285:2486-2497.
  • 5Rauch U,Osende JI,Chesebro JH,et al.Statins and cardiovascular diseases:the mutiple effects of lipid-lowing therapy by statins.Atherosclerosis,2000,153:181-189.

共引文献24

同被引文献285

引证文献35

二级引证文献183

;
使用帮助 返回顶部